21.68USD+4.03%Mkt Cap: 1.42B USDP/E: —Last update: 2026-05-22
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a cl…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap1.42B USD
Enterprise Value830.96M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-137.95M USD
Revenue/Share—
Last Price21.68 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.74
PEG—
EV/EBITDA-4.78
EV/Revenue—
P/S—
P/B2.66
EPS (TTM)-2.77
EPS (Forward)-3.63
52W Range
7.80084% of range24.25
52W High24.25 USD
52W Low7.800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.36%
ROA-32.01%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-106.83M USD
CapEx (TTM)280.00K USD
FCF Margin—
FCF Yield-4.80%
Net Debt-538.31M USD
Net Debt/EBITDA3.10
Balance Sheet
Debt/Equity0.00
Current Ratio13.85
Quick Ratio13.72
Book Value/Sh7.841 USD
Cash/Share8.215 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Target (Mean)31.46 USD
Target Range16.00 USD – 46.00 USD
# Analysts13
Ownership
Shares Out.65.70M
Float36.63M
Insiders10.22%
Institutions103.92%
Short Interest
Short Ratio15.7d
Short % Float18.96%
Short % Out.13.56%
Shares Short8.90M
Short (prev mo.)9.64M
Technical
SMA 5021.15 (+2.5%)
SMA 20016.93 (+28.0%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)504.03K
Avg Vol (10d)640.64K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—